-
1 Comment
From a valuation standpoint, the stock is 95.8% cheaper than other stocks from the sector with a price to sales ratio of 1.7.
Based on the above factors, Modern Chinese Medicine Group Co., Ltd gets an overall score of 1/5.
| ISIN | KYG6181B1068 |
|---|---|
| Exchange | HK |
| CurrencyCode | HKD |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| PE Ratio | 18.0 |
|---|---|
| Target Price | None |
| Beta | 0.34 |
| Market Cap | 216M |
| Dividend Yield | None |
Modern Chinese Medicine Group Co., Ltd., an investment holding company, engages in the production and sale of proprietary Chinese medicines for elderlies and middle aged in the People's Republic of China. It provides vigour and vitality supplement, circulation enhancement pills, cardiotonic enhancement capsules, heart wellness capsules, menstrual discomfort relief, liver detox tablets, liver-dispersing and stomach regulating pills, fever- removing and detoxification pills, kidney invigoration pills, and huoxiang zheng qi pills. The company offers its products as therapeutics for the treatment of qi-deficiency and blood-statis, cardio-cerebrovascular, digestive and gastrointestinal, gynecological, and for symptoms of COVID-19 and similar illnesses. It also provides business support, technical, and consulting services. The company was founded in 1986 and is headquartered in Chengde, China. Modern Chinese Medicine Group Co., Ltd. operates as a subsidiary of Modern Biotechnology Group Holdings Co., Ltd.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 1643.HK using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
